COO of Blueprint Medicines Corp (30-Year Financial, Insider Trades) Kate Haviland (insider trades) sold 13,334 shares of BPMC on 10/16/2020 at an average price of $101.23 a share. The total sale was $1.3 million.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667. Blueprint Medicines Corp has a market cap of $5.66 billion; its shares were traded at around $102.47 with and P/S ratio of 68.08. GuruFocus has detected 2 severe warning signs with Blueprint Medicines Corp. .
CEO Recent Trades:
- CEO and President Jeffrey W. Albers sold 5,000 shares of BPMC stock on 10/07/2020 at the average price of $99.17. The price of the stock has increased by 3.33% since.
Directors and Officers Recent Trades:
- COO Kate Haviland sold 13,334 shares of BPMC stock on 10/16/2020 at the average price of $101.23. The price of the stock has increased by 1.22% since.
- Principal Accounting Officer Ariel Hurley sold 600 shares of BPMC stock on 10/07/2020 at the average price of $100. The price of the stock has increased by 2.47% since.
- Director Mark Alan Goldberg sold 5,454 shares of BPMC stock on 10/07/2020 at the average price of $100. The price of the stock has increased by 2.47% since.
- Chief Scientific Officer Marion Dorsch sold 4,600 shares of BPMC stock on 10/06/2020 at the average price of $99. The price of the stock has increased by 3.51% since.
- Director Nicholas Lydon sold 9,815 shares of BPMC stock on 10/01/2020 at the average price of $93.08. The price of the stock has increased by 10.09% since.
For the complete insider trading history of BPMC, click here
.
